诺托金森化物R1通过抑制炎症和矩阵金属蛋白酶表达来减轻肌病变
Qingxin Han1, Junying Wu1, Yan Li1
1Department of Sports Medicine, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Frontiers in pharmacology
|July 23, 2025
概括
诺托金化物R1 (NGR1) 通过减少炎症和调节矩阵新陈代谢,有效治疗肌病. 这项研究揭示了NGR1作为肌病管理的有前途的治疗剂.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 肌病是一种使人虚弱的疾病,其特点是疼痛和功能障碍.
- 目前用于肌病的治疗方法有效性有限,并且可能会产生副作用.
- 对于有效的肌病治疗,需要新的治疗策略.
研究的目的:
- 评估Notoginsenoside R1 (NGR1) 在治疗肌病的治疗效果.
- 阐明NGR1发挥治疗作用的基础分子机制.
主要方法:
- 基于网络的分析 (PPI,GO,KEGG) 以确定潜在的NGR1目标.
- 在体内评估,使用原酶诱导的肌病变的老鼠模型.
- 在体外研究涉及脂多糖 (LPS) 诱导的十细胞炎症反应.
主要成果:
- 网络分析发现IL-6,TNF和MMP9是肌病中NGR1的关键标.
- 在大鼠中,NGR1在减轻原酶诱导的肌病症方面表现出剂量依赖的疗效.
- NGR1减弱了LPS诱导的炎症,并调节了原蛋白和矩阵金属蛋白酶在细胞中的合成.
结论:
- 诺托金化物R1 (NGR1) 通过调节炎症反应和矩阵新陈代谢,有效地缓解肌病的进展.
- NGR1为肌病的临床管理提供了一个有前途的治疗候选者.
相关概念视频
TGF - β Signaling Pathway
7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K


